The Bitter Disappointment of Apazunersen's Phase 3 Trial and the Challenges of Rare Disease Communication Following Market Close
Background
Angelman syndrome is a severe neurodevelopmental disorder caused by deletions or mutations in the UBE3A gene. It presents with complex symptoms including severe intellectual disability, loss of language, epileptic seizures, sleep disorders, and ataxia, making independent living impossible throughout life. Following the discovery that maternal UBE3A expression is silenced in neurons, the development of Antisense Oligonucleotide (ASO) therapies aimed at reactivating the suppressed paternal allele has been actively pursued.
Apazunersen stood at the forefront of this effort. Expectations from patient groups and academia reached their peak when news emerged from the early phase 1/2 open-label trial (NCT04259281) showing improvements in cognitive function and communication indicators. This was driven by the belief that a first therapeutic alternative capable of fundamentally regulating gene expression would emerge in the realm of rare diseases, where no treatments previously existed.
Based on early clinical results, the multinational phase 3 ASPIRE trial (NCT06617429) was rapidly designed. Patient families endured invasive intrathecal administration and frequent hospital visits, eagerly awaiting drug approval. However, the hurdle of a large-scale confirmatory trial, conducted with strict double-blinding including a placebo control group, proved much higher than expected.
Key Findings
On September 2, 2026, news broke that the phase 3 ASPIRE trial of apazunersen failed to meet its primary efficacy endpoint. The pharmaceutical company released a brief press release immediately after the stock market closed, announcing the clinical failure. The encouraging signs reported in the early phase 1/2 trials and ongoing additional studies (NCT07157254, NCT06415344) were not replicated with statistical significance in the large-scale controlled trial involving a placebo group.
The ASPIRE trial was a large-scale randomized controlled trial designed to ensure statistical power and aimed to mitigate observer bias and caregiver placebo effects common in open-label studies. In practice, neurodevelopmental assessment scales rely heavily on the subjective observations of parents or clinicians. It was difficult to strictly distinguish whether the patient improvements observed in the early trial stages without a placebo control were due to the drug's inherent biological activity or due to environmental changes resulting from the trial participation itself.
What the academic community noted in this announcement was not just the negative result itself. Because the significant news of the clinical discontinuation was handled only through a brief press release after market close, specific data on primary/secondary endpoints or biomarker responses were not transparently disclosed. Patient families and researchers were left in indefinite confusion, lacking clear information on which areas lacked efficacy or whether there were safety issues.
Implications and Outlook
This clinical failure serves as a reminder of how much caution is needed when interpreting early open-label data in the development of treatments for rare neurological diseases. The signals of functional improvement observed in the non-controlled arm cannot be definitively concluded as efficacy without rigorous comparative validation against the natural history of the disease. It has been proven once again that actual therapeutic benefits can only be demonstrated through placebo-controlled trials with statistical rigor.
The transparent disclosure of clinical trial data and methods of communication have also emerged as urgent issues for improvement. Patients and families participating in clinical trials are not mere subjects but core partners in drug development. The practice of companies focusing solely on stock price protection and regulatory risks while offering inadequate explanations after market close erodes the trust of the patient community. Even in failed trials, negative data—such as detailed responses by dosage or changes in UBE3A protein concentration in cerebrospinal fluid—must be fully disclosed to reduce trial and error in subsequent pipelines.
Moving forward, the development of neurological ASO therapies needs to move toward establishing more precise, objective evaluation tools. The active adoption of digital biomarkers, EEG measurements, and neuroimaging analysis to supplement subjective survey indicators is necessary to minimize interference from placebo effects. A culture of sharing data on painful failures with the academic community must be established so that the next steps toward overcoming Angelman syndrome are not in vain.
On Sept 2, 2026, negative results of the phase 3 ASPIRE trial (NCT06617429) of apazunersen in Angelman syndrome were announced in a press release issued after the stock market closed.1 Angelman syndrome is a severe neurodevelopmental condition causing intellectual disability, epilepsy, and behavioural disturbance.2 Expectations had been high, fuelled by encouraging findings from an ongoing open-label phase 1/2 trial of the compound (NCT04259281) and other trials that were still in progress (NCT07157254, NCT06415344).
The failure of the ASPIRE phase 3 trial and the process of its announcement present a fundamental turning point for the governance and communication protocols of rare disease clinical trials. Biopharmaceutical companies must establish guidelines for the transparent sharing of failure results in advance when designing patient-participatory clinical trials.
In actual clinical settings, it is highly likely that scenarios will involve the mandatory integration of digital biomarkers, such as sleep cycle measurement using wearable sensors and gait analysis, into protocols to overcome the limitations of subjective behavioral scales. Furthermore, regulatory authorities and Institutional Review Boards (IRBs) should institutionalize patient-centered communication channels to explain detailed data in stages to the patient community and researchers within a specified timeframe upon trial discontinuation.
If such a system is established, it will prevent unnecessary confusion for patient families and increase the success rate of developing next-generation gene therapies by using failed molecular designs and pharmacokinetic data as foundational knowledge.